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Abstract The non-homologous N-terminal regions of four 
human melanocortin (MC) receptors were truncated in order to 
investigate their putative participation in ligand binding. Eleven 
constructs were made, where different numbers of residues from 
the N terminus were deleted. These constructs were used for 
transient expression experiments in COS cells and analysed by 
ligand binding. The results show that 27, 25, 28, and 20 amino 
acids could be deleted from the N terminus of the human MC1, 
MC3, MC4 and MC5 receptors, respectively, including all 
potential N-terminal glycosylation sites in the MC1 and the 
MC4 receptors, without affecting ligand binding or expression 
levels. The results indicate that the N-terminal regions of the 
human MC1, MC3, MC4 and MC5 receptors, do not play an 
important role for the ligand binding properties of these 
receptors. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Pro-opiomelanocortin (POMC) is mainly expressed in the 
pituitary, hypothalamus and brain stem, and is post-transla-
tionally processed into the melanocortins, i.e. a-MSH (mela-
nocyte stimulating hormone), (3-MSH, y-MSH and ACTH 
(adrenocorticotropic hormone). Besides the well-known effects 
of ACTH on steroid production in the adrenal gland and oc-
MSH on pigmentation, the melanocortins display a broad 
array of additional physiological actions including effects on 
behaviour, memory, thermoregulation, pain perception, nerve 
regeneration, inflammation and blood pressure [1,2]. 
Five melanocortin receptor subtypes have been cloned [3-
7]. The MC1 receptor is expressed in melanocytes and has 
high affinity for a-MSH. The MC2 receptor is the ACTH 
receptor in the adrenal gland. The MC2 receptor has a distinct 
pharmacology from the other MC receptors as it binds ACTH 
with high affinity but not the MSH peptides [8]. The human 
MC3 and especially the human MC4 and MC5 receptors bind 
the MSH peptides with lower affinity than the human MC1 
receptor [9,10]. The physiological roles of these receptors are 
much less established compared to the MC1 and the MC2 
receptors. The MC3 receptor is expressed in the brain and 
also in the periphery where it has been found in the placenta, 
gut tissues and the heart [5,11]. The MC4 is predominantly 
found in the brain where it is widely distributed in almost 
every brain region [6,12]. Recently, it has been shown that 
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disruption of the MC4 receptor results in obesity [13]. The 
MC5 receptor is also found in the brain, but is more abun-
dantly expressed in peripheral tissues [7,14,15]. 
Very little is known about how the MSH peptides bind to 
the MC receptors. By use of site directed mutagenesis amino 
acids in the N terminal, extracellular loops (EL) [16] and in 
the transmembrane region (TM) 3 and TM6 [17] in the MC1 
receptor have been identified, which may participate in the 
ligand binding. Multiple mutations in TM4, EL2 and TM5 
in the MC3 receptor indicate that these regions may not in-
fluence specific ligand binding [18]. Two quite different 3D 
models of the MC1 receptor which were based on bacterio-
rhodopsin homology modelling and ligand docking in be-
tween the TM regions have been published [19,20]. The se-
quences of the MC receptor subtypes are highly conserved, 
particularly in the TM regions whereas the N-terminal regions 
varies quite a lot between the different subtypes. 
The aim of this study was to investigate a putative partic-
ipation of N-terminal regions of the human MC1, MC3, MC4 
and MC5 receptors in ligand binding. 
2. Materials and methods 
2.1. Chemicals 
[Nle4, D-Phe7]ct-MSH (NDP-MSH), a-MSH and P-MSH were pur-
chased from Saxon Biochemicals, Germany, or Bachem, Switzerland. 
NDP-MSH was radioiodinated by the Chloramine T method and 
purified by HPLC. 
2.2. Generation of truncated clones 
The truncated clones were made by PCR. Fragments of the wild 
type MC receptor clones were amplified by PCR, using downstream 
primers carrying a Hindlll linker and a ATG start codon for various 
positions in the N-terminal region of the MC receptors and an up-
stream primer with a Xhal linker. These PCR products were purified 
and cloned into Hindlll and Xbal sites of the pRc/CMV vector (In-
vitrogen) (or the pcDNA3.1/Zeo vector (Invitrogen), see Section 3), 
and the inserts and adjacent sequences of the vector DNA used for 
transfection experiments were confirmed by sequencing. The 3' end 
primer used for the MC1 clone was: GAC GTC TAG ATT CAC 
CAG GAG CAT GTC A (all primers are written in 5' to 3' direc-
tion), for the MC3 clones: GGT CTA GAC TAT CCC AAG TTC 
ATG CCG, for the MC4 clones: GAC GTC TAG ATT CAA TAT 
CTG CTA GAC AAG GTC, for the MC5 clones: GAC GTC TAG 
ATT CAA TCC CTT CTG GGA AAG CT. The 5' end primer used 
for the MC1ATG28 clone was: GGG AAG CTT CAC ATA TGC 
AGA CAG GAG CCC GGT, for the MC3AT044 clone: GGA AGC 
TTG AAT GCC CTC TGT TCA GCC AAC A, for the MC3ATGB1 
clone: GGA AGC TTG AAT GCC TAA TGG CTC GGA GCA C, 
for the MC3ATG63 clone: GGG AAG CTT CAC ATA TGA GCA 
ACC AGA GCA GCA GCG CCT, for the MC3ATG69 clone: GGA 
AGC TTG AAT GAA TGC TTC GTG CTG C, for the MC4ATG24 
clone: GGG AAG CTT CAC ATA TGA GCA ATG CCA GTG 
AGT, for the MC4ATG29 clone: GGG AAG CTT CAC ATA TGT 
CCC TTG GAA AAG GCT A, for the MC4ATG35 clone: GGG AAG 
CTT CTC ATA TGT CTG ATG GAG GGT GCT A, for the 
M C 5 A T G I 4 c l o n e . G G G A A G C T T C A C A T A T G A A T G C C A 
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Fig. 1. Alignment of the N-terminal amino acid sequences of the cloned human MC receptors (MC2 not included) with the mutant clones de-
scribed in the text. Numbers in parentheses denote the accession numbers in EMBL and GenBank Data Libraries. Borders between the N-ter-
minal region and TMl are as proposed [19]. Potential N-terminal glycosylation sites are boxed. (1) The human MC3 receptor is displayed from 
the Met38 as the preceding sequence may not be expressed [21]. (2) Constructs which did not give rise to specific binding after transfection are 
denoted by (—) and the others by (+). 
CAG AGG GCA, for the MC5ATG21 clone: GGG AAG CTT CAC 
ATA TGT CAG GAC CAA ATG TCA and for the MC5ATG28 clone: 
GGG AAG CTT CAC ATA TGA AGT CTT CAC CAT GTG A. 
2.3. Cells and expression 
The wild type human MC1 and human MC5 receptor [3,7] were 
cloned into the expression vector pRc/CMV (Invitrogen). The wild 
type human MC3 and human MC4 receptor DNA, cloned into the 
expression vector pCMV/neo, were a gift from Dr. Ira Gantz [5,6], 
For receptor expression, COS-1 cells were grown in Dulbecco's modi-
fied Eagle's medium with 10% foetal calf serum. Eighty percent con-
fluent cultures were transfected with the DNA mixed with liposomes 
in serum free medium (for details see [10]). After transfection, the 
serum-free medium was replaced with growth medium and the cells 
were cultivated for about 48 h. Cells were then scraped off, centri-
fuged, and used for radioligand binding. 
2.4. Binding studies 
The transfected cells were washed with binding buffer [9] and dis-
tributed into 96-well micro titer plates (approximately 40000 cells/ 
well). The cells were then incubated for 2 h at 37°C with 0.05 ml 
binding buffer in each well, containing the same concentration of 
[125I]NDP-MSH and appropriate concentrations of an unlabelled li-
gand. After incubation, the cells were washed with 0.2 ml of ice-cold 
binding buffer and detached from the plates with 0.2 ml of 0.1 M 
NaOH. Radioactivity was counted (Wallac, Wizard automatic gamma 
counter) and data analysed with a software package for radioligand 
binding analyses (Wan System, Umea, Sweden). Data were analysed 
by fitting it to formulas derived from the law of mass-action by the 
method generally referred to as computer modelling. For saturation 
analysis, 12 concentrations of [125I]NDP-MSH in the range of 0.02 up 
to 20 nM were used. Non-specific binding was determined in the 
presence of 3 itM NDP-MSH. The binding assays were performed 
in duplicate wells and repeated three times. Untransfected COS-1 cells 
did not show any specific binding to [125I]NDP-MSH. 
3. Results 
Eleven truncated clones of the human MC1, MC3, MC4 
and MC5 receptors were created in order to investigate the 
putative participation of the N terminus in ligand binding (see 
schematic representation of the clones in Fig. 1). The human 
wild type MC receptors and truncated clones were used for 
expression experiments in COS-1 cells which were subse-
quently tested in binding assays using [125I]NDP-MSH as ra-
dioligand. The truncated clones expressed at levels similar to 
the wild type clones, except the MC3ATG69 , MC4ATG35 and 
MC5ATG28 which did not show any specific binding in the 
COS-1 cells after transfection (data not shown). Saturation 
curves for the wild type and the MC1A T G 2 8 , MC3ATG63, 
M C 4 A T G 2 9 a n d MC5ATG2i c i o n e S 5 a r e shown in Fig. 2. Com-
petition curves of different MSH-peptides for the same recep-
tors are shown in Fig. 3. In Table 1, the Ki values obtained 
from the computer analysis of these data are shown together 
with the Kd values for [
125I]NDP-MSH obtained from the 
saturation curves. 
We have earlier shown that the comparatively long cDNA 
derived N-terminal sequence of the human MC3 receptor up 
to ATG38 does not participate in ligand binding [21]. Further 
truncation of the human MC3, as well as the human MC4 
and human MC5 receptors resulted in clones termed 
M C 3 A T G 4 4 ! M ^ A T C S ^ M C 4
A T G 2 4 and MC5ATG14. When 
these constructs were expressed they bound NDP-MSH (oc-
MSH) in similar fashion as respective wild type receptor 
(see Table 1). Deletion of additional amino acids from these 
receptors and the MC1 receptor, resulted in clones termed 
MC1A T G 2 8 , MC3ATG63, MC4ATG29 and MC5ATG21. These 
clones were expressed and fully characterised by ligand 
binding using both saturation analysis ([125I]NDP-MSH) 
and competition analysis (NDP-MSH, cc-MSH and p*-MSH). 
The results show (Table 1) that the binding constants of 
the MSH peptides for these truncated receptors are in-
distinguishable from those of the corresponding wild 
type receptors. Moreover, the binding constants presented 
in Table 1 are in close agreement to those found earlier 
for the wild type MC1, MC3, MC4 and MC5 receptors 
[9,10,22]. 
Additional constructs, termed MC3ATG69 , MC4ATG35 and 
MC5ATG28 did not show any specific binding to labelled 
NDP-MSH when transfected to COS-1 cells. We made two 
clones of each of these constructs, and we also cloned the 
M C 4 A T G 3 5 a n d t h e M C 5 A T G 2 8 i n t 0 t h e pcDNA3.1/Zeo vector 
(in addition to the pRc/CMV vector) without creating any 
specific binding in COS-1 cells after transfection. 
Fig. 2. Saturation curves of [125I]NDP-MSH obtained from transfected COS cells. The figures show total binding (■) and binding in the pres-
ence of 3 uM unlabeled NDP-MSH (•) for the wild type and MC1ATG28, MC3ATG63, MC4ATG29, MC5ATG21 clones. Lines represent the com-
puter modelled best fit of the data using an one-site model. 
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Fig. 3. Competition curves of NDP-MSH (■), a-MSH (•), P-MSH ( A ) obtained on transfected COS cells using a fixed concentration of 
nM [125I]NDP-MSH for the different MC receptor clones. 
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Table 1 
K[ and KA (nmol/1) values (mean ± S.E.M) obtained from competition and saturation curves using [
126I]NDP-MSH and different MSH ana-
logues on transfected COS-1 cells 
ReceptorLigond 
MC1 
M C 1 A T G 2 9 
MC3 
M C 3 A T G 4 4 
M C 3 A T G 5 1 
M C 3 A T G 6 3 
MC4 
M C 4 A T G 2 4 
M C 4 A T G 2 9 
MC5 
M C 5 A T G 1 4 
M C 5 A T G 2 1 
Ki 
[125I]NDP-MSH 
0.109 ±0.062 
0.144 ±0.027 
0.394 ±0.061 
nd 
nd 
0.435 ±0.036 
2.29 ±0.27 
nd 
2.59 ±0.22 
2.86 ±0.71 
nd 
1.44 ±0.23 
Ki 
NDP-MSH 
0.046 ±0.011 
0.050 ±0.015 
0.493 ±0.035 
0.534 ±0.092 
0.413 ±0.038 
0.593 ±0.044 
1.86±0.35 
1.05 ±0.10 
1.28 ±0.28 
2.65 ±0.37 
1.09 ±0.21 
2.15 ±0.20 
a-MSH 
0.210 ±0.089 
0.141 ±0.090 
53.2 ±9.62 
nd 
31.2 ±4.2 
34.4 ±5.8 
2030 ±410 
1730 ±630 
957 ±319 
4990 ±800 
5570 ±1730 
3270 ±1080 
P-MSH 
2.53 ±0.93 
2.75 ±0.66 
57.0 ±12.0 
nd 
nd 
64.8 ±7.8 
642 ±150 
nd 
513 ±150 
13 900 ±5 600 
nd 
10100 ±1700 
nd, not determined. 
4. Discussion 
For most G-protein coupled receptors, in particular those 
serving as recognition sites for low molecular weight com-
pounds like adrenaline, the ligand binding pocket is thought 
to be localised between the TM regions, which are predicted 
to form oc-helices analogous to the extensively characterised 
bacteriorhodopsin. For other G-protein coupled receptors 
that bind small peptides, like neurokinins [23], enkephalins 
[24] or secretin and vasoactive intestinal polypeptide [25] the 
N-terminal region is known to play an role for the ligand 
binding. For glycoprotein hormone receptors [26] the N-ter-
minal region can be even more important, such as for the 
lutropin/chorigonadotropin receptor, where the N-terminal 
domain alone is sufficient for high affinity hormone binding 
[27]. Truncations of G-protein coupled receptors have been 
shown to both increase or decrease ligand affinities [28]. The 
melanocortin receptor family has the shortest amino acid se-
quence among the superfamily of G-protein coupled recep-
tors. The human MC1, MC2, MC3, MC4 and MC5 receptors 
are 317, 297, 361 (or 324 [21]), 333, 325 amino acids long, 
respectively. They are characterised by having short N- (ca. 
25-39 amino acids) and C-terminal regions (ca. 17-21 amino 
acids) as well as a very small second extracellular loop (ca. 9 
amino acids). 
Our present results show that 27 amino acids of the human 
MC1, 25 amino acids of the human MC3 receptor, 28 amino 
acids of the human MC4 receptor and 20 amino acids from 
the human MC5 receptor could be deleted from the N termini 
without affecting the expression or binding of [125I]NDP-
MSH, NDP-MSH, a-MSH or B-MSH. Further deletions of 
the N termini resulted in 'total loss of binding', which may 
have been caused by misfolding or problems with the mem-
brane integration of the receptor. 
Our results show that all potential N-terminal glycosylation 
sites can be removed from the MC1 and MC4 receptors 
(MClAsn15, MClAsn29, MC4Asn3, MC4Asn17 and 
MC4Asn26) as well as two potential glycosylation sites 
(Asn53 and Asn39) from the MC3 receptor and three potential 
sites from the MC5 receptor (Asn2, Asn15 and Asn20) without 
causing any effects on ligand binding or expression. Our re-
sults thus indicate that N-terminal glycosylation is unlikely to 
play an important role in the folding and membrane targeting 
of the MC receptors. 
It remains unclear whether the non-binding clones 
(MC3ATG69, MC4ATG35 and MC5ATG28) were expressed and 
inserted into the cell membrane. It is unlikely that the com-
plete absence of specific ligand binding for these constructs 
was caused by deletion of residues crucial for ligand binding 
while all other deletions did not even change the ligand bind-
ing properties at all. Structural or expression complications, 
or influence on the integration of the receptors to the cell 
membrane are more probable explanations. 
The precise border between the extracellular N-terminal 
part and TM1 is not known. Amino acids proposed to pre-
cede TM1, like the conserved Glu (MClGlu36) and positive 
charges may be important for the structure, folding or ligand 
binding. Moreover, the conserved Cys (MClCys34) which may 
form a disulphide bridge with a corresponding Cys residue in 
extracellular loop 3 (or even elsewhere in the receptor) may 
also be important for receptor structure. The observation that 
the MC1A T G 2 8 is giving binding, but not the equally truncated 
MC5ATG28, may indicate important role for amino acids pre-
ceding the TM1. A recent analysis of G-protein coupled re-
ceptors revealed, that those lacking a leader sequence, like 
the MC receptors, have a high preference for a positive 
charge in the N terminus close to TM1[29]. This is in con-
trast to the more general 'positive inside' rule developed 
earlier [30] and may indicate a specific role for Lys32 and 
Lys28 in the MC4 and the MC5 receptors, respectively. 
Thus, the loss of a positive charge may play some role in 
the loss of binding observed, but no such positive charge ex-
ists in the MC3 receptor. In the latter case one might spec-
ulate that a lack of hydrophilic residues in the N-terminal 
region, besides the earlier mentioned conserved Glu, might 
cause problems in membrane insertion and orientation of 
TM1. 
All the MC receptors have a Ser residue close to the N-
terminal end (MClSer6, MC3Ser4, MC4Ser4 and MC5Ser4). 
This Ser was recently proposed to participate in ligand bind-
ing based on the finding that a Ser/Ala exchange in the MC1 
receptor resulted in loss in affinity to NDP-MSH and oc-MSH 
[16]. Our data contradict those previous results but at present 
we do not have any rational explanation to this discrepancy. 
In summary, our results indicate that neither the N-terminal 
regions nor carbohydrates added by glycosylation of these are 
likely to be essential for ligand binding for the human MC 
receptors or for their structural fidelity. 
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